Company Fundamental

Laurus Labs Limited


Company & Business Profile

Laurus Labs Limited is the leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in Generic Active Pharmaceutical Ingredients (APIs) for select, high-growth Therapeutic areas of Anti-Retrovirals (ARVs) and Hepatitis C.

The company also manufacture APIs in Oncology and other Therapeutic areas. The strategic and early investments in R&D and Manufacturing infrastructure have enabled them to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing “Donor-Funded Access-to-Medicines Markets” of Sub-Saharan Africa, South-East Asia and Latin America.

During the financial year 2016, Laurus Labs Limited sold their APIs in 32 countries. The company also has growing Synthesis and Nutraceutical/Cosmeceutical Ingredients businesses. Further, they are increasingly focusing towards growing their integrated generics Finished Dosage Forms (FDFs) business.

Apply in IPO now in ASBA mode, to apply call us at 0731-4217261. Read http://bit.ly/2gelM2d to know further

Tags: IPOFundamental


Search Reports

SEARCH

Open an account

OPEN AN ACCOUNT

Reports

Daily Currency Market...

HIGHLIGHTS: The U.S. dollar...

Read More

Daily Market Update...

Nifty opened on a subdued...

Read More

Daily Market Update...

Nifty opened higher traded in...

Read More

Daily Metal & Agro Buzz:

HIGHLIGHTS: India imported...

Read More

Daily Currency Market...

HIGHLIGHTS: The U.S. dollar...

Read More

INFOSYS Q1FY20 RESULT...

Infosys management has raised...

Read More

INDUSIND BANK RESULT...

We expect merger with Bharat...

Read More

TORNTPHARM

SHORT TERM TRADING CALL: BUY...

Read More

ULTRA TECH CEMENT

SHORT TERM TRADING CALL: BUY...

Read More

UPL

SHORT TERM TRADING CALL: BUY...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions.